From the Mater Misericordiae University Hospital, Dublin, Ireland.
Thoracic Oncology Program, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
Cancer J. 2020 Nov/Dec;26(6):543-547. doi: 10.1097/PPO.0000000000000493.
Blockade of the programmed cell death 1 immune inhibitory pathway has revolutionized the treatment of advanced non-small cell lung cancer and led to significant improvements in overall survival. In contrast, early-stage surgically resectable lung cancer has had few treatment advances in many years and continues to be associated with a high risk of relapse despite apparent curative resection. In this review, we discuss the many ongoing efforts to incorporate programmed cell death 1 pathway blockade into the treatment paradigm for surgically resectable lung cancer both as adjuvant and neoadjuvant therapy. We review the early-phase results from neoadjuvant clinical trials, the landscape of phase III trials that are ongoing, and look to the future of immune checkpoint blockade as a potential curative therapy for surgically resectable lung cancer.
程序性细胞死亡 1 免疫抑制通路的阻断治疗彻底革新了晚期非小细胞肺癌的治疗方法，并显著改善了总生存期。相比之下，近年来早期可手术切除的肺癌治疗进展甚微，尽管根治性切除后复发风险仍然很高。在这篇综述中，我们讨论了将程序性细胞死亡 1 通路阻断治疗纳入可手术切除肺癌的辅助和新辅助治疗模式的多项正在进行的努力。我们回顾了新辅助临床试验的早期结果、正在进行的 III 期临床试验的现状，并展望免疫检查点阻断作为可手术切除肺癌潜在治愈疗法的未来。
